<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-145888" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Managing Fresh-Frozen Plasma Transfusion Adverse Effects: Allergic Reactions, TACO, and TRALI</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bharadwaj</surname>
            <given-names>Meghana S.</given-names>
          </name>
          <aff>Sawai Man Singh Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bora</surname>
            <given-names>Vaibhav</given-names>
          </name>
          <aff>Augusta University- Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Meghana Bharadwaj declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vaibhav Bora declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-145888.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Fresh-frozen plasma transfusion is a vital component of modern medical practice, employed in various clinical scenarios to manage coagulation disorders and support patients in need. While fresh-frozen plasma is undeniably beneficial, it is crucial to recognize that, like any medical intervention, it carries potential risks and adverse effects that healthcare providers must be well-prepared to manage. Among the spectrum of adverse effects, this discussion&#x000a0;mainly focuses on&#x000a0;3 significant categories: allergic reactions, transfusion-associated circulatory overload, and transfusion-related acute lung injury. While varying in their presentation and mechanisms, these complications underscore the importance of thorough understanding and vigilant monitoring in the administration of&#x000a0;fresh-frozen plasma&#x000a0;to ensure both its effectiveness and the safety of transfusion recipients.</p>
        <p>Blood is a circulating specialized body fluid containing components such as plasma, red blood cells, platelets, and white blood cells. Whole blood is separated into components by centrifugation due to the components' different densities and sedimentation rates.&#x000a0;Centrifugation of whole blood leads to red cells settling at the bottom and white cells settling above the red cells. Platelets form a layer above the white cells. A refrigerated centrifuge is a device used to separate blood and its components. Whole blood is subjected to a heavy spin (5000G), which yields packed red blood cells, platelet-poor plasma, buffy coat, and fresh-frozen plasma. The light spin (1500G) of the centrifuge is utilized to yield platelet-rich plasma.<xref ref-type="bibr" rid="article-145888.r1">[1]</xref>&#x000a0;The components are also separated using apheresis. Apheresis is a procedure used to collect blood components from a single donor in one session. Whole blood is collected from a voluntary donor and stored in bags with CPDA (citrate-phosphate-dextrose-adenine) solution.&#x000a0;</p>
        <p>Fresh-frozen plasma is a part of whole blood that is fractionated and frozen within 8 hours to preserve the coagulation factors. Plasma was one of the first blood components developed during World War II military trauma resuscitation. In 1936, Dr. John Elliott mentioned that plasma could be used as a blood substitute in traumatic shock. Dr. Max Strumia developed freeze-dried plasma for military use.<xref ref-type="bibr" rid="article-145888.r2">[2]</xref>&#x000a0;Post World War II, plasma transfusion became more common in medical management. Over time, increased screening of blood-borne diseases and improved safety measures have&#x000a0;reduced complications related to plasma transfusion.<xref ref-type="bibr" rid="article-145888.r3">[3]</xref></p>
        <p>Fresh-frozen plasma can be stored at -25 &#x000b0;C or below for up to 36 months. Fresh-frozen plasma comprises labile and stable coagulation factors,&#x000a0;plasma proteins, fibrinogen, and factor VIII. The temperature helps in preserving the labile coagulation factors. The factors present are fibrinogen, factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, protein S, protein C, antithrombin III, and Von-Willebrand factor antigen.<xref ref-type="bibr" rid="article-145888.r4">[4]</xref>&#x000a0; Fresh-frozen plasma&#x000a0;is thawed using a water bath at 37&#x000b0;C. Once thawed,&#x000a0;the&#x000a0;plasma&#x000a0;should be transfused promptly. If it is not possible to administer the transfusion immediately, the plasma&#x000a0;should be stored and used within 4 hours maintained at a temperature of 22 &#x000b1;2&#x000b0;C, or a maximum of 120 hours if stored at a temperature of 4 &#x000b1;2&#x000b0;C.&#x000a0;</p>
        <p>Transfusion is indicated&#x000a0;in the context of single or multiple coagulation factor deficiencies, acute disseminated intravascular coagulation, immediate reversal of warfarin effect, thrombotic thrombocytopenic purpura, massive transfusion, liver disease, special pediatric considerations, and cardiopulmonary bypass surgeries. Transfusion reactions with fresh-frozen plasma can range from minor to life-threatening. They can be classified as acute or delayed, immunologic and non-immunologic.<xref ref-type="bibr" rid="article-145888.r5">[5]</xref></p>
        <p>Acute transfusion reactions include acute hemolytic, allergic, anaphylactic, febrile nonhemolytic, bacterial contamination, transfusion-related acute lung injury (TRALI), and transfusion-associated circulatory overload (TACO). Delayed transfusion reactions include delayed hemolytic transfusion reaction, transfusion-transmitted infection, and post-transfusion purpura.&#x000a0;If a reaction is suspected, transfusion must be stopped immediately, and the blood bank and treating physician must be notified.<xref ref-type="bibr" rid="article-145888.r6">[6]</xref></p>
      </sec>
      <sec id="article-145888.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Acute transfusion reactions may be immune- or nonimmune-mediated reactions that occur immediately or within 24 hours of fresh-frozen plasma transfusion. The different types of reactions can be attributed to various etiologies.<xref ref-type="bibr" rid="article-145888.r7">[7]</xref></p>
        <p>Fresh-frozen plasma transfusion reactions have been attributed to factors such as human leukocyte antigen (anti-HLA) and human neutrophil antigen(anti-HNA) antibodies. Class II HLA antibodies are more commonly associated.&#x000a0;</p>
        <p>Allergic transfusion reactions&#x000a0;are due to the preformed antibodies binding to transfused donor allergens. Identification of specific proteins to which recipients react has been challenging. Commonly implicated are human immunoglobulin (IgA) and haptoglobin. IgA antibodies have been implicated in many anaphylactic transfusion reactions, primarily observed in IgA-deficient individuals. Methylene blue-treated plasma has also been involved in anaphylactic reactions associated with plasma.<xref ref-type="bibr" rid="article-145888.r7">[7]</xref></p>
        <p>Febrile nonhemolytic transfusion reaction (FNHTR) associated with plasma transfusion is low as fresh-frozen plasma is considered acellular. FNHTR is thought to be due to the immune response to leukocytes in the blood. Instances of FNHTR can be attributed to&#x000a0;white blood cells&#x000a0;contaminating plasma that has survived the freeze-thaw process.<xref ref-type="bibr" rid="article-145888.r8">[8]</xref> Acute hemolytic transfusion reactions (AHTR) with fresh-frozen plasma are commonly seen due to ABO-incompatible plasma transfusion with higher titers of isohemagglutinins. Red cell fragments within plasma can also cause&#x000a0;red blood cell allo-immunization.<xref ref-type="bibr" rid="article-145888.r6">[6]</xref></p>
        <p>TRALI is caused due to damage to pulmonary endothelium mediated by activated neutrophils. A "2-hit" model is also considered: The first hit is the priming of neutrophils on the pulmonary endothelium due to the preexisting medical condition of the patient, and the second hit is the transfusion (containing antibodies) activating the primed neutrophils causing endothelial damage. The commonly implicated antibodies in the donor plasma include HLA and HNA. Plasma from a female donor with a history of pregnancy is a risk factor for TRALI.<xref ref-type="bibr" rid="article-145888.r9">[9]</xref></p>
        <p>The etiology of&#x000a0;TACO is multifactorial, with several risk factors contributing to its development.&#x000a0;These risks&#x000a0;include cardiac failure, renal failure, positive fluid balance, advanced age, suboptimal fluid management, and rapid transfusion rates. Elevated levels of cytokines, such as interleukin 8 (IL-8) and interleukin 10 (IL-10), have been observed in patients with TACO. The exact mechanism for fluid accumulation in the lungs in&#x000a0;TACO is being investigated.<xref ref-type="bibr" rid="article-145888.r10">[10]</xref></p>
        <p>Nonimmunologic reactions include bacterial contamination, circulatory overload, and chemical reactions like citrate toxicity. Infection risk with plasma transfusion is minimal due to extensive screening and testing. Transmissible infections include HIV, hepatitis B, and C. Bacterial contamination is rare, but contamination by water baths during thawing has been reported.&#x000a0;<italic toggle="yes">Staphylococcus, Klebsiella, Propionibacterium, </italic>and<italic toggle="yes"> Pseudomonas</italic> are some of the implicated organisms.<xref ref-type="bibr" rid="article-145888.r11">[11]</xref></p>
        <p>Delayed transfusion reactions occur between 24 hours and 30 days. These reactions are due to amnestic responses to previously exposed foreign antigens. They include hemolytic reactions and transfusion-associated graft versus host disease (TA-GVHD). Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare condition, primarily because thawed units of fresh-frozen plasma typically do not contain viable lymphocytes, essential for developing the graft-versus-host disease reaction.<xref ref-type="bibr" rid="article-145888.r7">[7]</xref></p>
      </sec>
      <sec id="article-145888.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>In the United States, 282 transfusion reactions are reported&#x000a0;for every 100,000 transfusions administered. The incidence of adverse reactions related to fresh-frozen plasma transfusion&#x000a0;shows substantial variation. Average reported rates of transfusion reactions with fresh-frozen plasma are as follows:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Allergic reactions: 92 for every 100,000 units transfused.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Anaphylactic reactions: 0.8 for every&#x000a0;100,000 units transfused.</p>
          </list-item>
          <list-item>
            <p>Febrile nonhemolytic transfusion reactions (FNHTRs): 12 for every 100,000 units transfused.</p>
          </list-item>
          <list-item>
            <p>Transfusion-associated circulatory overload (TACO): 6 for every&#x000a0;100,000 units transfused.</p>
          </list-item>
          <list-item>
            <p>Transfusion-related acute lung injury (TRALI): 1.8 for every&#x000a0;100,000 units transfused.<xref ref-type="bibr" rid="article-145888.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>Posttransfusion risk of&#x000a0;HBV infection is estimated to be about 1:357,000 to 1:280,000 per transfusion. HIV and HCV are estimated to be 1:1,467,000 and 1:1,149,000, respectively, in the United States.<xref ref-type="bibr" rid="article-145888.r13">[13]</xref></p>
      </sec>
      <sec id="article-145888.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Acute Transfusion Reactions</bold>
</p>
        <p>Allergic transfusion reactions can manifest as urticarial or anaphylactic responses. These reactions occur when the recipient's antibodies react against foreign proteins in the donor plasma. In most cases, the reactions are mild and present with symptoms like urticaria, pruritus, flushing, and isolated fever.&#x000a0;Anaphylactic reactions present with symptoms such as rashes, angioedema, upper and lower airway obstruction, and hypotension.&#x000a0;Individuals with IgA deficiency are at a higher risk of anaphylactic transfusion reactions due to the presence of alloantibodies against IgA. Deficiencies in other plasma proteins, such as haptoglobin, can also result in anaphylaxis when exposed through&#x000a0;fresh-frozen plasma transfusion.&#x000a0;An ongoing discussion revolves around the potential involvement of immunoglobulin E (IgE) in urticarial transfusion reactions. Some studies suggest a contribution of IgE in these reactions, while others do not, highlighting the complexity of the mechanisms involved in allergic responses during transfusions.<xref ref-type="bibr" rid="article-145888.r14">[14]</xref><xref ref-type="bibr" rid="article-145888.r15">[15]</xref></p>
        <p>Methylene-blue treated plasma&#x000a0;has caused allergic transfusion reactions. In cases of allergen-independent pathways, biological response modifiers (BRMs), including inflammatory cytokines and chemokines, which accumulate during storage in blood components, have been identified as potential triggers for allergic reactions. These components can lead to immune responses in recipients, even in the absence of specific allergens.<xref ref-type="bibr" rid="article-145888.r16">[16]</xref></p>
        <p>An FNHTR is a&#x000a0;febrile response caused by cytokines released from blood donor leukocytes. Incompatible donor antibodies recognizing recipient antigens as foreign are also attributed to FNHTR pathology. FNHTR can also be mediated by bioactive mediators released by the remaining leukocytes during the freeze-thaw process. FNHTRs can also be influenced by the number of viable leukocytes present after the freeze-thaw process in blood products. The presence of viable leukocytes can contribute to these febrile reactions during transfusions. Leucoreducation has been shown to decrease the rates of FNHTR.<xref ref-type="bibr" rid="article-145888.r8">[8]</xref></p>
        <p>Hemolytic transfusion reactions (HTR) encompass two primary types: immediate and delayed hemolytic transfusion reactions (DHTR). These reactions involve the destruction of red blood cells and can occur immediately during the transfusion or be delayed, manifesting days to weeks after the transfusion. ABO-incompatible&#x000a0;fresh-frozen plasma units have been shown to cause hemolytic reactions based on&#x000a0;the titers of isohemagglutinins in the donor plasma. Whenever possible, ABO-compatible plasma is preferable to avoid HTR; if unavailable, it is essential to consider plasma with low titers of anti-A and anti-B.<xref ref-type="bibr" rid="article-145888.r17">[17]</xref></p>
        <p>Viruses and bacteria can cause transfusion-transmitted infections. Notable transfusions-associated&#x000a0;pathogens include human immunodeficiency virus (HIV), hepatitis B, and hepatitis C. These infections can be transmitted through contaminated blood products, emphasizing the importance of rigorous screening and safety measures in blood transfusion practices. Cytomegalovirus and human T-cell lymphotropic virus are typically not transmitted through fresh-frozen plasma because&#x000a0;fresh-frozen plasma&#x000a0;is an acellular blood component.&#x000a0;Safety measures include retesting of plasma, known as donor-retested plasma, where units are quarantined until a follow-up negative infectious disease test from the donor, and pathogen-reduced plasma, treated with UV light or chemicals like methylene blue, to curb lipid-enveloped virus transmission, particularly outside the United States. Solvent/detergent (S/D) plasma is a method that eliminates the risk of transmission of enveloped viruses in blood products, further bolstering the safety of plasma transfusions. These techniques are crucial for reducing the potential transmission of infectious agents in blood components.<xref ref-type="bibr" rid="article-145888.r18">[18]</xref></p>
        <p>In transfusion-related acute lung injury (TRALI), the primary mechanism involves generating and activating neutrophils within the pulmonary endothelium. Two main pathophysiological mechanisms are implicated in TRALI: antibody-mediated and nonantibody-mediated (see&#x000a0;<bold>Image.</bold>&#x000a0;Pathophysiology of TRALI). Both mechanisms can lead to acute lung injury following a blood transfusion. A 2-hit hypothesis often explains TRALI. The first hit is the preexisting clinical condition of the patient, which may prime or sensitize the pulmonary endothelium and neutrophils. The second hit is the transfusion of blood or blood components, which can activate these primed neutrophils, ultimately leading to the development of acute lung injury. This dual mechanism underscores the complexity of TRALI's pathophysiology.</p>
        <p>Risk factors for the first hit include shock, liver surgery, current smoking,&#x000a0;chronic alcohol abuse, higher peak airway pressure, positive fluid balance, low IL-10 levels, and systemic inflammation. In cases of TRALI, elevated C-reactive protein levels are often observed, reflecting an inflammatory response. Transient leukopenia, a temporary decrease in white blood cell count, may also be part of the immune reaction. Additionally, donor antibodies against human leukocyte antigens (HLA) and human neutrophil antigens (HNA) are&#x000a0;commonly implicated in TRALI, contributing to immune-mediated lung injury.&#x000a0;Nonantibody-mediated TRALI occurs when no detectable anti-HLA or HNA antibodies are present, but the reaction is still triggered by other unidentified antigens or biological reactive molecules (BRM).<xref ref-type="bibr" rid="article-145888.r10">[10]</xref><xref ref-type="bibr" rid="article-145888.r19">[19]</xref></p>
        <p>Transfusion-Aassociated circulatory overload is characterized by pulmonary hydrostatic edema, which results in the accumulation of protein-poor edema fluid in the lungs. The specific pathways leading to this condition are still a subject of ongoing research. A 2-hit hypothesis is also considered a pathophysiological mechanism for&#x000a0;TACO&#x000a0;similar to TRALI.&#x000a0;TACO is associated with several risk factors, including positive fluid balance, congestive heart failure, and renal failure. When these risk factors are combined with fluid overload or the rapid infusion of blood products, it can lead to TACO. During TACO, an increase in inflammatory cytokines such as IL-6 is often observed, and fever is a common clinical finding. These factors contribute to the pathophysiology and clinical presentation of TACO.<xref ref-type="bibr" rid="article-145888.r20">[20]</xref></p>
        <p>
<bold>Delayed Transfusion Reactions</bold>
</p>
        <p>Delayed hemolytic transfusion reactions result from an anamnestic response to a foreign protein, which can be non-ABO, such as the Duffy blood group antigen. Sensitization to this foreign protein often occurs due to prior transfusion or pregnancy, leading to an immune response upon reexposure during a subsequent transfusion. In contrast, transfusion-associated graft-versus-host disease (TA-GVHD) is rare in cases of plasma transfusion, as plasma is typically devoid of viable lymphocytes, which are necessary for developing TA-GVHD. Due to the freeze-thaw process, the number of viable lymphocytes capable of causing TA-GVHD is negligible.&#x000a0;Posttransfusion purpura is an uncommon condition caused by an immune response to alloantibodies, which leads to severe thrombocytopenia. This condition typically develops within 5 to 10 days following the transfusion of plasma components, and it can result in bleeding and purpura, or small purple or red spots on the skin caused by bleeding into the skin.<xref ref-type="bibr" rid="article-145888.r21">[21]</xref></p>
      </sec>
      <sec id="article-145888.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Before beginning a transfusion, assessing the patient's medical history and vital signs is crucial. Previous medical history of IgA deficiency, haptoglobin deficiency, congestive heart failure, renal failure, transfusion history, and family and social history must be elicited. Verification of the patient details and details on the blood/blood component bag before initiation of transfusion is essential. Vitals should be recorded every 15 minutes or put on a constant monitor. The patient must be evaluated for&#x000a0;signs of fever, chills, urticaria, angioedema, hypotension, and respiratory distress. Slight variation in vitals signs is normal. In trauma and critically ill patients, closely monitoring the transfusion rate is vital. Remaining vigilant for the signs and symptoms of TRALI and TACO, as early detection and prompt intervention are crucial to ensuring patient safety during transfusion therapy.<xref ref-type="bibr" rid="article-145888.r22">[22]</xref></p>
        <p>Allergic transfusion reactions present with urticaria, pruritus, and flushing. Anaphylactic reactions can present with more severe symptoms and signs of dyspnea, wheezing, angioedema, chest tightness, nausea, vomiting, tachycardia, hypotension, and shock. In FNHTR, patients may present with fever&#x000a0;and chills.&#x000a0;<xref ref-type="bibr" rid="article-145888.r23">[23]</xref></p>
        <p>Hemolytic transfusion reactions can manifest with a range of symptoms, including fever, abdominal pain, and the presence of red or brown-colored urine. Patients experiencing these reactions may also exhibit chills, hypotension, and back pain.&#x000a0;In severe cases, patients may exhibit signs of renal failure or disseminated intravascular coagulation, reflecting the systemic consequences of red blood cell destruction and hemoglobin release. Early recognition and immediate intervention are essential to prevent further complications in these cases.<xref ref-type="bibr" rid="article-145888.r24">[24]</xref></p>
        <p>Both TACO and TRALI are characterized by acute onset of respiratory distress within&#x000a0;6 hours of receiving a blood or blood component transfusion. They show features of bilateral infiltrates on a chest x-ray indicative of pulmonary edema and hypoxemia with SpO<sub>2</sub> less than 90% on room air and hypotension. See <bold>Table.&#x000a0;</bold>TACO vs TRALI Signs and Symptoms for a comparison of the signs and symptoms of the 2 conditions. The clinical criteria for TRALI as published by an expert panel in 2019:<xref ref-type="bibr" rid="article-145888.r25">[25]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>TRALI Type&#x02009;I. Patients with no risk factors for ARDS and satisfy the following criteria:
<list list-type="bullet"><list-item><p>Acute onset, hypoxemia (P/F ratio&#x02009;&#x02264;&#x02009;300 or SpO<sub>2</sub> &#x0003c;&#x02009;90% on room air), evidence of bilateral pulmonary edema on imaging, no evidence of left atrial hypertension or,&#x000a0;if present, not the main contributor to the hypoxemia</p></list-item><list-item><p>Onset during or within 6&#x02009;hours of transfusion</p></list-item><list-item><p>No alternative risk factor for acute respiratory distress syndrome (ARDS)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>TRALI Type&#x02009;II. Patients with risk factors for ARDS (but who have not been diagnosed with ARDS) or who have existing mild ARDS but whose respiratory status deteriorates&#x000a0;due to transfusion and&#x000a0;with both of the following:
<list list-type="bullet"><list-item><p>Acute onset, with hypoxemia, bilateral pulmonary edema, no evidence of left atrial hypertension</p></list-item><list-item><p>Stable respiratory status in the 12&#x02009;hours before transfusion</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>In TACO cases, acute respiratory distress, distended neck veins, rales on auscultation, the presence of S3 heart sound on auscultation, hypertension, and fever may be present. The clinical definition of TACO, as&#x000a0;outlined by the National Healthcare Safety Network in 2016, is as follows:<xref ref-type="bibr" rid="article-145888.r10">[10]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>New onset or exacerbation of &#x02265;3&#x000a0;symptoms within 6 hrs of transfusion:
<list list-type="bullet"><list-item><p>Acute respiratory distress (dyspnea, orthopnea, and cough)&#x000a0;</p></list-item><list-item><p>Evidence of positive fluid balance</p></list-item><list-item><p>Elevated brain natriuretic peptide&#x000a0;</p></list-item><list-item><p>Radiographic evidence of pulmonary edema&#x000a0;</p></list-item><list-item><p>Evidence of left heart failure&#x000a0;</p></list-item><list-item><p>Elevated central venous pressure&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Delayed transfusion reactions have signs of fever, jaundice, and a decline in hemoglobin concentration 2 to 4 weeks after transfusion. Posttransfusion purpura presents with sudden severe bleeding from mucous membranes, gastrointestinal tract, urinary tract, or intracranial hemorrhage due to severe thrombocytopenia within 2 weeks of transfusion. Other symptoms include fever, chills, and&#x000a0;platelet transfusion refractoriness.<xref ref-type="bibr" rid="article-145888.r21">[21]</xref></p>
      </sec>
      <sec id="article-145888.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Identification of signs and symptoms plays a crucial role in treating transfusion reactions. An initial assessment must be&#x000a0;performed to determine the reaction severity. Symptoms include fever, chills, urticaria, itching, respiratory distress, or hypotension.&#x000a0;Patients with mild transfusion reactions generally display minimal alterations in their vital signs and clinical symptoms. These mild reactions can involve a slight increase in temperature, usually within the range of 1 to 2 degrees Celsius from their baseline, and transient urticaria (hives) without any associated systemic symptoms or significant physiological changes.<xref ref-type="bibr" rid="article-145888.r26">[26]</xref></p>
        <p>In case of a reaction,&#x000a0;the transfusion must be stopped immediately. Transfusion reaction protocol, if present, must be activated. The blood bank should be notified. The&#x000a0;label on the plasma component and all associated&#x000a0;records must be checked for possible clerical errors. Examination of the unit to check for discoloration and clumps must be undertaken.&#x000a0;Venous access must be maintained. Assess the airway, breathing, and circulation of the patient. The patient must be evaluated for hypotension and shock, severe respiratory distress, sepsis, severe rigors or pain, fever, rash, or urticaria. After initial stabilization of the patient, additional&#x000a0;investigations must be undertaken, and a decision to resume or discontinue the transfusion must be made.<xref ref-type="bibr" rid="article-145888.r26">[26]</xref></p>
        <p>Investigations on the&#x000a0;pre-reaction and post-reaction plasma&#x000a0;transfusions are performed&#x000a0;to detect hemolysis or jaundice. Blood cultures are collected if a septic reaction is suspected. In cases of allergic and anaphylactic reactions, basophil activation test (BAT) results and tryptase levels can be evaluated. If IgA or Haptoglobin deficiency is suspected, plasma levels can be investigated. In AHTR investigation, peripheral smear,&#x000a0;bilirubin, haptoglobin, lactate dehydrogenase, coombs test, and total counts can be evaluated.&#x000a0;In the cases of TRALI and TACO, chest X-ray, B-type natriuretic peptide (BNP), and NT-proBNP can be obtained. It is essential to determine if there is circulatory overload. Total blood counts can be used to evaluate DHTR and posttransfusion purpura.<xref ref-type="bibr" rid="article-145888.r27">[27]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-145888.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>After&#x000a0;the clinical assessment of the patient, symptomatic management is undertaken. If hypotension and shock are present, fluids and vasopressors are administered. In cases of severe respiratory distress, oxygen supplementation, epinephrine, antihistamines, and corticosteroids are administered. If signs of volume overload are present, administer IV diuretics and oxygen. In cases of sepsis, obtain blood cultures and administer broad-spectrum antibiotics. Treat fever with antipyretics and rash or urticaria with antihistamines.<xref ref-type="bibr" rid="article-145888.r26">[26]</xref></p>
        <p>Allergic transfusion reactions are managed depending on the reaction severity.&#x000a0;For mild acute transfusion reactions, systemic antihistamines&#x000a0;are used. If the patient's symptoms improve with the initial management, it may be possible to resume the transfusion under careful monitoring. In case the symptoms persist, transfusion must be stopped. In cases of severe allergic reaction and anaphylaxis, the airway, breathing, and circulation must be assessed. Epinephrine (1:1000) is a first-line drug.&#x000a0;Oxygen supplementation, IV fluids, methylprednisolone or prednisolone, and antihistamines are other supportive measures. In cases of bronchospasm,&#x000a0;bronchodilators or &#x003b2;2-agonists must be administered. In cases of IgA deficiency, transfusions from IgA-deficient donors must be sought.<xref ref-type="bibr" rid="article-145888.r23">[23]</xref></p>
        <p>FNHTRs are transient. Treatment is by administering&#x000a0;paracetamol/acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs). In cases of suspected transfusion-transmitted infections, blood cultures should be drawn from the patient, and broad-spectrum IV antibiotics should be started. The transfusion of ABO-compatible plasma can avoid AHTR.<xref ref-type="bibr" rid="article-145888.r8">[8]</xref></p>
        <p>If TRALI is suspected, immediate cessation of the transfusion is essential. The airway is assessed, and high-flow O<sub>2</sub>&#x000a0;therapy is initiated. Mechanical ventilation should be considered when improvements do not occur with high-flow oxygen therapy. The patient is evaluated for fluid overload, and a chest x-ray is obtained. Lung protective ventilation strategies are used with low tidal volume and high positive end-expiratory&#x000a0;pressure (PEEP)&#x000a0;as the pathology is similar to ARDS. The management is mainly supportive. Research in transfusion medicine explores various potential therapies for managing and preventing transfusion-related adverse events. These experimental approaches include IL-10 therapy, blocking IL-8 receptors, and downregulating C-reactive protein (CRP) levels.<xref ref-type="bibr" rid="article-145888.r10">[10]</xref><xref ref-type="bibr" rid="article-145888.r28">[28]</xref></p>
        <p>In the case of TACO, the elevation of the head-end of the bed, oxygen supplementation, and administration of diuretics lead to rapid improvement. Noninvasive positive pressure ventilation can improve respiratory status. Optimal fluid management and treatment of underlying conditions are essential in management. In case of worsening respiratory symptoms, intubation and mechanical ventilation must be initiated. Lung-protective ventilation strategies must be implemented.<xref ref-type="bibr" rid="article-145888.r10">[10]</xref></p>
        <p>See <bold>Table.</bold> FFP Reactions for the signs, symptoms, and management of fresh-frozen plasma transfusion reactions.</p>
      </sec>
      <sec id="article-145888.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Depending on the type of transfusion reaction, various differential diagnoses should be considered:</p>
        <list list-type="bullet">
          <list-item>
            <p>ARDS</p>
          </list-item>
          <list-item>
            <p>Anaphylaxis</p>
          </list-item>
          <list-item>
            <p>Disseminated intravascular coagulation</p>
          </list-item>
          <list-item>
            <p>Septicemia</p>
          </list-item>
          <list-item>
            <p>Cardiogenic pulmonary edema</p>
          </list-item>
          <list-item>
            <p>Infections</p>
          </list-item>
        </list>
        <p>TRALI and TACO&#x000a0;have similar presentations. Differentiating TRAIL and TACO from ARDS is necessary. All&#x000a0;3 conditions present with respiratory distress and have similar findings&#x000a0;on chest x-ray. Echocardiography&#x000a0;helps in the identification of volume status and diastolic dysfunction. Pulmonary artery occlusion pressure and protein concentration in pulmonary edema fluid are&#x000a0;assessed, but findings are not definitive. B-type natriuretic peptide (BNP) and N-terminal pro&#x02013;B-type natriuretic peptide (NT-proBNP) biomarker levels in conjunction with clinical signs and symptoms are used&#x000a0;to&#x000a0;establish&#x000a0;the diagnosis of TACO.<xref ref-type="bibr" rid="article-145888.r29">[29]</xref></p>
      </sec>
      <sec id="article-145888.s9" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>Adverse effects range from simple allergic reactions to life-threatening reactions such as TACO and TRALI. Simple reactions can be handled in the inpatient unit, whereas more severe reactions warrant ICU care. TRALI and TACO may require intubation and mechanical ventilation. Multidisciplinary management with the involvement of transfusion specialists, intensivists, nurses, and respiratory therapists is essential for improvement in patient outcomes. Mitigation strategies in blood collection and processing are necessary to prevent reactions like TRALI. These strategies include checking for antibodies (HLA, HNA),&#x000a0;excluding female donors with a history of pregnancy, and avoiding multiparous donors.<xref ref-type="bibr" rid="article-145888.r5">[5]</xref></p>
        <p>Preventing adverse effects in blood transfusions begins at the collection stage. Male donors are often preferred, as female donors may possess antibodies due to pregnancy that are capable of causing adverse effects. Other measures include checking the bag to avoid clerical errors, monitoring during transfusion, and early identification of symptoms and treatment.&#x000a0;</p>
      </sec>
      <sec id="article-145888.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Allergic transfusion reactions, febrile nonhemolytic transfusion reactions, and hemolytic transfusion reactions associated with plasma transfusions have a good prognosis. Trauma patients who receive fresh-frozen plasma transfusions may be at increased risk of developing additional conditions, such as ARDS and multiorgan failure, following their initial injuries.<xref ref-type="bibr" rid="article-145888.r30">[30]</xref>&#x000a0;Critically ill patients are at an increased risk of experiencing complications associated with fresh-frozen plasma transfusion.<xref ref-type="bibr" rid="article-145888.r31">[31]</xref></p>
        <p>Patients with TRALI generally have a favorable prognosis. They often experience clinical improvement within 3 to 4 days following the initial event. Pulmonary infiltrates typically resolve relatively quickly. However, in some cases, these infiltrates might persist for more than 7 days, highlighting the variability in the recovery process among TRALI patients.<xref ref-type="bibr" rid="article-145888.r32">[32]</xref></p>
      </sec>
      <sec id="article-145888.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Plasma transfusion can lead to various complications, from mild allergic reactions to severe and life-threatening conditions like TACO and TRALI. Allergic transfusion reactions, while generally not causing significant clinical sequelae, can necessitate additional workup and prolong the hospital stay for the affected patient. On the other hand, FNHTRs typically resolve quickly with the administration of antipyretic therapy. Prompt recognition and appropriate management are essential in addressing these complications and ensuring patient safety.</p>
        <p>TRALI often worsens the patient's respiratory status and is primarily managed with supportive measures. TRALI is associated with a mortality rate that typically ranges from 5 to 10%, underscoring the severity of this condition.<xref ref-type="bibr" rid="article-145888.r33">[33]</xref>&#x000a0;TACO can have even more significant mortality and morbidity. One study reported mortality rates in the range of 14-29%, signifying the potentially life-threatening nature of this condition.<xref ref-type="bibr" rid="article-145888.r34">[34]</xref></p>
      </sec>
      <sec id="article-145888.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Engaging in a patient-centered conversation about the need for plasma transfusion is crucial. This discussion should cover the reasons for the transfusion, its potential advantages and drawbacks, and the safety precautions, including crossmatching and vigilant monitoring. Patients should also be educated about common symptoms linked to transfusion reactions and encouraged to report any unusual sensations promptly. Providing patients with the opportunity to ask questions and seek additional information ensures they are well informed and empowered to make informed decisions about their healthcare.<xref ref-type="bibr" rid="article-145888.r26">[26]</xref></p>
      </sec>
      <sec id="article-145888.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Fresh-frozen plasma is collected using a citrate-containing anticoagulation solution, which can lead to citrate toxicity when administered. Citrate acts by chelating calcium, resulting in hypocalcemia, which can produce a range of symptoms. These symptoms may encompass hypotension, arrhythmias, alterations in mental status, increased central venous pressure (CVP), and clinical signs like Chvostek and Trousseau. The treatment for citrate toxicity involves calcium supplementation to correct the hypocalcemia and alleviate these symptoms.<xref ref-type="bibr" rid="article-145888.r35">[35]</xref></p>
        <p>To mitigate the risk of TRALI, several key strategies are employed. These encompass donor screening for antibodies like anti-HLA and anti-neutrophil antibodies and the preference for plasma and platelet donations from only male donors or females who haven't experienced pregnancy. Utilizing pathogen-reduced, washed, or volume-reduced blood components also helps minimize TRALI risk. Alongside these measures, close monitoring during and after transfusions is essential, coupled with comprehensive healthcare provider education, to ensure early recognition and timely treatment of TRALI cases, collectively enhancing the overall safety of blood transfusions.<xref ref-type="bibr" rid="article-145888.r36">[36]</xref></p>
        <p>Mitigation strategies for TACO encompass a multifaceted approach, including pretransfusion risk assessment and&#x000a0;administering volume-reduced, leukoreduced, and washed blood products. Maintaining slow transfusion rates, administering diuretics before and after transfusion, and ensuring optimal fluid management are critical components of TACO prevention and management.<xref ref-type="bibr" rid="article-145888.r20">[20]</xref></p>
      </sec>
      <sec id="article-145888.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Fresh-frozen plasma transfusions have increased steadily over the years. Even with evidence-based guidelines guiding usage, transfusion has increased in patients with abnormal coagulation studies who are not bleeding. All interprofessional healthcare team members, including physicians, advanced practice practitioners, nursing staff, and pharmacists, should know the indications and adverse reactions associated with fresh-frozen plasma administration. During fresh-frozen plasma transfusion patients, the patient's vital signs, including pulse, blood pressure, oxygen saturation, and temperature, must be monitored before, during, and after transfusion. Healthcare workers should familiarize themselves with the symptomatology of adverse events and act immediately if they suspect a transfusion reaction.</p>
        <p>The blood and blood products must be checked with the patient's records before transfusion to avoid clerical errors. If a previous history of transfusion reaction is present, precautions must be taken to prevent a repeat reaction. If a transfusion reaction is suspected during transfusion, the transfusion must be stopped immediately, and the blood bank must be notified. Life-threatening reactions such as TRALI and TACO must be identified&#x000a0;swiftly to provide supportive management and improve outcomes.</p>
        <p>Local and national hematovigilance networks&#x000a0;must be utilized&#x000a0;as a source of information and&#x000a0;contacted to report adverse events. Fresh-frozen plasma transfusion is safer now than in previous years, but clinicians&#x000a0;must be prepared for the potential risks of transfusion.&#x000a0;</p>
        <p>The interprofessional healthcare team enhances patient care and outcomes when addressing adverse reactions and complications from fresh-frozen plasma transfusions. Physicians, advanced practitioners, nurses, pharmacists, and other allied healthcare professionals collaborate seamlessly to ensure a well-coordinated response. Clinicians provide clinical expertise to promptly diagnose and treat adverse events, tailoring interventions based on the patient's needs. Nursing staff closely monitor vital signs and observe for early warning signs of adverse reactions, immediately reporting any concerns. Pharmacists offer valuable insights into medication management and compatibility during the transfusion process. Effective communication and collaboration within the team are fundamental, allowing for a swift and comprehensive response to minimize patient harm and optimize transfusion outcomes. This coordinated effort ensures that patient safety remains at the forefront of&#x000a0;fresh-frozen plasma transfusion management.</p>
      </sec>
      <sec id="article-145888.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=145888&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=145888">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/managing-fresh-frozen-plasma-transfusion-adverse-effects-allergic-reactions-taco-and-trali/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=145888">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/145888/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=145888">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-145888.s16">
        <fig id="article-145888.image.f1" position="float" orientation="portrait">
          <caption>
            <p>TACO vs TRALI Signs and Symptoms. Transfusion-associated circulatory overload (TACO) versus transfusion-related acute lung injury (TRALI) signs and symptoms. Contributed by Meghana Bharadwaj, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="TACO__vs__TRALI" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145888.s17">
        <fig id="article-145888.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Pathophysiology of TRALI Contributed by Meghana Bharadwaj, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="TRALI" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145888.s18">
        <fig id="article-145888.image.f3" position="float" orientation="portrait">
          <caption>
            <p>FFP Reactions. Signs, symptoms, and management of fresh-frozen plasma transfusion reactions. Contributed by Meghana Bharadwaj, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="transfusion__adverse__effects" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-145888.s19">
        <title>References</title>
        <ref id="article-145888.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kulkarni</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Overview of blood components and their preparation.</article-title>
            <source>Indian J Anaesth</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>5</issue>
            <fpage>529</fpage>
            <page-range>529-37</page-range>
            <pub-id pub-id-type="pmid">25535413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strumia</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Monaghan</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>THE INTRAVENOUS USE OF SERUM AND PLASMA, FRESH AND PRESERVED.</article-title>
            <source>Ann Surg</source>
            <year>1940</year>
            <month>Apr</month>
            <volume>111</volume>
            <issue>4</issue>
            <fpage>623</fpage>
            <page-range>623-9</page-range>
            <pub-id pub-id-type="pmid">17857568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watson</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Plasma Transfusion: History, Current Realities, and Novel Improvements.</article-title>
            <source>Shock</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>46</volume>
            <issue>5</issue>
            <fpage>468</fpage>
            <page-range>468-479</page-range>
            <pub-id pub-id-type="pmid">27380536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Heymann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Spies</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meinck</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wernecke</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Kiesewetter</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pruss</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Activity of clotting factors in fresh-frozen plasma during storage at 4 degrees C over 6 days.</article-title>
            <source>Transfusion</source>
            <year>2009</year>
            <month>May</month>
            <volume>49</volume>
            <issue>5</issue>
            <fpage>913</fpage>
            <page-range>913-20</page-range>
            <pub-id pub-id-type="pmid">19159416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Khawar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Guzman</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <chapter-title>Fresh Frozen Plasma (FFP)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>9</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">30020719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Suddock</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Crookston</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <chapter-title>Transfusion Reactions</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">29489247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pandey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vyas</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of plasma transfusion.</article-title>
            <source>Transfusion</source>
            <year>2012</year>
            <month>May</month>
            <volume>52 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>65S</fpage>
            <page-range>65S-79S</page-range>
            <pub-id pub-id-type="pmid">22578374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shmookler</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Educational Case: Febrile Nonhemolytic Transfusion Reaction.</article-title>
            <source>Acad Pathol</source>
            <year>2020</year>
            <season>Jan-Dec</season>
            <volume>7</volume>
            <fpage>2374289520934097</fpage>
            <pub-id pub-id-type="pmid">32728618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roubinian</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>TACO and TRALI: biology, risk factors, and prevention strategies.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2018</year>
            <month>Nov</month>
            <day>30</day>
            <volume>2018</volume>
            <issue>1</issue>
            <fpage>585</fpage>
            <page-range>585-594</page-range>
            <pub-id pub-id-type="pmid">30570487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Semple</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Rebetz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-associated circulatory overload and transfusion-related acute lung injury.</article-title>
            <source>Blood</source>
            <year>2019</year>
            <month>Apr</month>
            <day>25</day>
            <volume>133</volume>
            <issue>17</issue>
            <fpage>1840</fpage>
            <page-range>1840-1853</page-range>
            <pub-id pub-id-type="pmid">30808638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hillyer</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Josephson</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Blajchman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vostal</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2003</year>
            <fpage>575</fpage>
            <page-range>575-89</page-range>
            <pub-id pub-id-type="pmid">14633800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saadah</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>van Hout</surname>
                <given-names>FMA</given-names>
              </name>
              <name>
                <surname>Schipperus</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>le Cessie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Middelburg</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wiersum-Osselton</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>van der Bom</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Comparing transfusion reaction rates for various plasma types: a systematic review and meta-analysis/regression.</article-title>
            <source>Transfusion</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>57</volume>
            <issue>9</issue>
            <fpage>2104</fpage>
            <page-range>2104-2114</page-range>
            <pub-id pub-id-type="pmid">28766723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Epstein</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Holmberg</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Progress in monitoring blood safety.</article-title>
            <source>Transfusion</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>7</issue>
            <fpage>1408</fpage>
            <page-range>1408-12</page-range>
            <pub-id pub-id-type="pmid">20636529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Homburger</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Laschinger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Naylor</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Pineda</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Measurement of anti-IgA antibodies by a two-site immunoradiometric assay.</article-title>
            <source>Transfusion</source>
            <year>1981</year>
            <season>Jan-Feb</season>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-44</page-range>
            <pub-id pub-id-type="pmid">7008284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimada</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tadokoro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Niihara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Isa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moriya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ashida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mitsunaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakajima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Juji</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies.</article-title>
            <source>Transfusion</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>766</fpage>
            <page-range>766-73</page-range>
            <pub-id pub-id-type="pmid">12147031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirayama</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment.</article-title>
            <source>Br J Haematol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>160</volume>
            <issue>4</issue>
            <fpage>434</fpage>
            <page-range>434-44</page-range>
            <pub-id pub-id-type="pmid">23215650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bers&#x000e9;us</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Boman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nessen</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Westerberg</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma.</article-title>
            <source>Transfusion</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>53 Suppl 1</volume>
            <fpage>114S</fpage>
            <page-range>114S-123S</page-range>
            <pub-id pub-id-type="pmid">23301963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marietta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Franchini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bindi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Picardi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ruggeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Silvestro</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Is solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document.</article-title>
            <source>Blood Transfus</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>277</fpage>
            <page-range>277-286</page-range>
            <pub-id pub-id-type="pmid">27136429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tung</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Chiaretti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Sultana</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Reade</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>YL</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-related acute lung injury (TRALI): Potential pathways of development, strategies for prevention and treatment, and future research directions.</article-title>
            <source>Blood Rev</source>
            <year>2022</year>
            <month>May</month>
            <volume>53</volume>
            <fpage>100926</fpage>
            <pub-id pub-id-type="pmid">35065815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bulle</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Klanderman</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Pendergrast</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cserti-Gazdewich</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Callum</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vlaar</surname>
                <given-names>APJ</given-names>
              </name>
            </person-group>
            <article-title>The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload.</article-title>
            <source>Blood Rev</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>52</volume>
            <fpage>100891</fpage>
            <pub-id pub-id-type="pmid">34627651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hawkins</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aster</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Post-Transfusion Purpura: Current Perspectives.</article-title>
            <source>J Blood Med</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>405</fpage>
            <page-range>405-415</page-range>
            <pub-id pub-id-type="pmid">31849555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Lotterman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Blood Transfusion</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">29762999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savage</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Tobian</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Ness</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Scratching the surface of allergic transfusion reactions.</article-title>
            <source>Transfusion</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>53</volume>
            <issue>6</issue>
            <fpage>1361</fpage>
            <page-range>1361-71</page-range>
            <pub-id pub-id-type="pmid">22998777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rout</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harewood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramsey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Master</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <chapter-title>Hemolytic Transfusion Reaction</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">28846280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vlaar</surname>
                <given-names>APJ</given-names>
              </name>
              <name>
                <surname>Toy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Looney</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Juffermans</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Bux</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bolton-Maggs</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Silliman</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Kor</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kleinman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A consensus redefinition of transfusion-related acute lung injury.</article-title>
            <source>Transfusion</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>59</volume>
            <issue>7</issue>
            <fpage>2465</fpage>
            <page-range>2465-2476</page-range>
            <pub-id pub-id-type="pmid">30993745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakdash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yazer</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>What every physician should know about transfusion reactions.</article-title>
            <source>CMAJ</source>
            <year>2007</year>
            <month>Jul</month>
            <day>17</day>
            <volume>177</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-7</page-range>
            <pub-id pub-id-type="pmid">17638948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soutar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McSporran</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tomlinson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Booth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grey</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Guideline on the investigation and management of acute transfusion reactions.</article-title>
            <source>Br J Haematol</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>201</volume>
            <issue>5</issue>
            <fpage>832</fpage>
            <page-range>832-844</page-range>
            <pub-id pub-id-type="pmid">37211954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Semple</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>McVey</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rebetz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuebler</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Targeting Transfusion-Related Acute Lung Injury: The Journey From Basic Science to Novel Therapies.</article-title>
            <source>Crit Care Med</source>
            <year>2018</year>
            <month>May</month>
            <volume>46</volume>
            <issue>5</issue>
            <fpage>e452</fpage>
            <page-range>e452-e458</page-range>
            <pub-id pub-id-type="pmid">29384784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tobian</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sokoll</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Tisch</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ness</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>N-terminal pro-brain natriuretic peptide is a useful diagnostic marker for transfusion-associated circulatory overload.</article-title>
            <source>Transfusion</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>1143</fpage>
            <page-range>1143-50</page-range>
            <pub-id pub-id-type="pmid">18298592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watson</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Sperry</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rosengart</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Minei</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Harbrecht</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Cuschieri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Billiar</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Peitzman</surname>
                <given-names>AB</given-names>
              </name>
              <collab>Inflammation and Host Response to Injury Investigators</collab>
            </person-group>
            <article-title>Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome.</article-title>
            <source>J Trauma</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>221</fpage>
            <page-range>221-7; discussion 228-30</page-range>
            <pub-id pub-id-type="pmid">19667872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Belsher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Afessa</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Winters</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Hubmayr</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Gajic</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients.</article-title>
            <source>Chest</source>
            <year>2007</year>
            <month>May</month>
            <volume>131</volume>
            <issue>5</issue>
            <fpage>1308</fpage>
            <page-range>1308-14</page-range>
            <pub-id pub-id-type="pmid">17400669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Webert</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Blajchman</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-related acute lung injury.</article-title>
            <source>Transfus Med Rev</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>252</fpage>
            <page-range>252-62</page-range>
            <pub-id pub-id-type="pmid">14571393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Popovsky</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-Related Acute Lung Injury: Incidence, Pathogenesis and the Role of Multicomponent Apheresis in Its Prevention.</article-title>
            <source>Transfus Med Hemother</source>
            <year>2008</year>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>76</fpage>
            <page-range>76-79</page-range>
            <pub-id pub-id-type="pmid">21512631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roubinian</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Hendrickson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Triulzi</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Gottschall</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kor</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Looney</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Matthay</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kleinman</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Brambilla</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>EL</given-names>
              </name>
              <collab>NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)</collab>
            </person-group>
            <article-title>Incidence and clinical characteristics of transfusion-associated circulatory overload using an active surveillance algorithm.</article-title>
            <source>Vox Sang</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>112</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-63</page-range>
            <pub-id pub-id-type="pmid">28001313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Citrate metabolism in blood transfusions and its relationship due to metabolic alkalosis and respiratory acidosis.</article-title>
            <source>Int J Clin Exp Med</source>
            <year>2015</year>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>6578</fpage>
            <page-range>6578-84</page-range>
            <pub-id pub-id-type="pmid">26131288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145888.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Otrock</surname>
                <given-names>ZK</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-related acute lung injury risk mitigation: an update.</article-title>
            <source>Vox Sang</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>112</volume>
            <issue>8</issue>
            <fpage>694</fpage>
            <page-range>694-703</page-range>
            <pub-id pub-id-type="pmid">28948604</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
